Following the AACR Annual Meeting 2023, our team of expert researchers at Beacon have examined all 155 ADC-relevant abstracts that were presented at the conference. We have compiled their findings, along with additional insights, into one convenient infographic.
The infographic highlights:
- A comprehensive analysis of the 155 ADC abstracts showcased at AACR 2023
- The top targets of all 122 ADC module-relevant drugs presented
- A deep dive into the popular TROP-2 target, with a spotlight on developers by geographic region
To learn more about our findings from AACR 2023, or how Beacon ADC can enhance your data needs and provide fast insights, please book a research session below or contact us directly on beacon@hansonwade.com.
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
Speak with our team
Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.
